BioAge Labs, Inc. (NASDAQ: BIOA)

BioAge Labs, Inc. is a clinical stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases by targeting the biology of human aging.

The company generates revenue through collaboration agreements with Lilly and Novartis and through an option agreement with JiKang Therapeutics which may provide upfront payments milestones and potential royalties.

As a pre revenue entity BioAge Labs, Inc does not yet have product sales.

BioAge Labs, Inc occupies an early stage position in the biopharmaceutical industry focusing on novel targets derived from human aging biology. Its proprietary platform leverages longitudinal multi omic data from more than twenty five thousand participants to identify drug targets such as NLRP3 and the apelin receptor. While no NLRP3 inhibitor is currently approved the company faces competition from programs at Ventyx Biosciences NodThera Roche Merck Novo Nordisk AstraZeneca Neumora Ventus Tenvie Insilico Brenig and Zydus. For its apelin receptor agonist program competitors include Structure Therapeutics Bristol Myers Squibb APIE Therapeutics and Sanofi. The company’s competitive advantages stem from its unique human data sets its ability to pinpoint mechanistically distinct targets and its early stage pipeline that addresses large unmet needs in cardiometabolic disease.

The company’s current customers include pharmaceutical collaborators such as Lilly Novartis and JiKang Therapeutics with whom it has research option and licensing agreements. In the future BioAge Labs, Inc aims to serve patients suffering from metabolic diseases including cardiovascular risk and diabetic macular edema.